A recent clinical trial could change the face of therapy for a very aggressive and stubborn form of breast cancer: triple-negative. A combination of chemotherapy and immunotherapy boosts survival rates, the scientists found.
Triple-negative breast cancer is so called since its cells lack receptors for two hormones (estrogen and progesterone) and one protein (HER2).
